The role of long-acting injection in schizophrenia treatment and future challenges

Masakazu Hatano, Hiroyuki Kamei, Nakao Iwata

Research output: Contribution to journalArticlepeer-review

Abstract

Long-acting injection is a controlled release agent, which was designed that stable blood concentration is provided by giving it once in two to four weeks. Schizophrenia treatment is essential to long-term medication. So, LAI is one of the useful therapeutic strategies. Although traditional LAI had the strong negative impression to be forcibly used for the patients with the refusing medication and the lack of insight into disease, LAI of second-generation antipsychotics are expected to maintenance therapy for the outpatients with Schizophrenia. While psychiatric medical care is shifting from hospitalization to outpatient department, and a role of LAI is important in social rehabilitation. Here, we outline to the clinical importance, characteristic, and future challenge of LAI in psychiatric treatment.

Original languageEnglish
Pages (from-to)186-193
Number of pages8
JournalDrug Delivery System
Volume31
Issue number3
DOIs
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'The role of long-acting injection in schizophrenia treatment and future challenges'. Together they form a unique fingerprint.

Cite this